bluuebunny/crossref_metadata_2025_split huggingface dataset:
BASELINE CHARACTERISTICS IN A RANDOMIZED PLACEBO-CONTROLLED STUDY OF THE EFFECTS OF THE SIX PLANT EXTRACTS COMBINATION TOTUM-854 ON BLOOD PRESSURE MANAGEMENT: THE INSIGHT STUDY
Authors: Ripoche Doriane , Otero Yolanda F. , Bargetto Maxime , Sapone Veronique , Noblet Fanny , Cazaubiel Murielle , Peltier Sebastien , Sirvent Pascal , Bard Jean -MARIE 
Published: May 2024

Objective:
Arterial Hypertension (AHT) is a major cause of premature death worldwide. Polyphenolic compounds have shown promising effects in hypertension management. TOTUM-854 (T-854), a polyphenol-rich composition derived from six plant extracts, has potential in reducing the risk of developing AHT. The primary aim of this study is to evaluate the efficacy of T-854 in reducing systolic blood pressure in individuals with moderately elevated blood pressure.

Design and method:
The INSIGHT clinical trial is a multi-center, multi-country, randomized, double-blinded study, evaluating T-854 in individuals with high-normal and grade I hypertension who are not on medication affecting blood pressure. This trial assesses the impact of 3.71g of T-854 daily over 12 weeks on systolic blood pressure (SBP) reduction (AOBP, Automated Office Blood Pressure). Secondary objectives include effects on diastolic AOBP, blood lipids, glucose levels, hsCRP and anthropometric parameters.

Results:
A total of 412 participants (men 60% and women 40%) have been recruited across 3 countries, with a mean age of 45 years. According to the inclusion criteria, the population consists of individuals with high-normal (47%) or grade I hypertension (53%). A significant proportion exhibits anthropometric abnormalities (45% overweight, 25% obese). Some participants also show moderate metabolic abnormalities, notably total cholesterol over 5 mmol/L (49%) and fasting blood sugar levels above 5.5 mmol/L (25%). These characteristics align with those typically found in the general population, where elevated blood pressure often coexists with metabolic disorders related to overweight and obesity.

Conclusions:
In conclusion, the recruited population meets the study's inclusion criteria and is well-suited to evaluate the efficacy of T-854 in managing moderately elevated blood pressure. The study results are anticipated in mid-2024.
IN ARTERIAL HYPERTENSION THE RIGHT VENTRICLE IS NO LONGER THE “FORGOTTEN CAVITY”
Authors: Nicolae Camelia , Paun Nicolae , Uscoiu Gabriela , Munteanu Andreea Madalina , Iliesiu Adriana Mihaela , Nanea Ioan Tiberiu 
Published: May 2024

Objective:
The right ventricle showed late interest in the assessment and stratification of the severity of arterial hypertension. The complex systemic reaction in the context of arterial hypertension, represented in particular by the activation of the renin angiotensin aldosterone system and the increase in sympathetic activity would suggest an early impairment of diastolic and later systolic function also of the right ventricle. Echocardiography is the most accessible way to evaluate the right ventricle in medical practice.
Purpose of the study: to evaluate the precocity and the type of right ventricular function impairment in recently diagnosed hypertensive patients.

Design and method:
The patients were included after following the recommendations for the diagnosis of arterial hypertension according to the guide published by ESH in 2023. Personal biological data and parameters, cardiovascular risk factors, blood pressure values were recorded. Patients with other comorbidities, with secondary hypertension were excluded.Patients on antihypertensive treatment were also excluded.
We investigated echocardiographically by analyzing 2D diastolic parameters, Doppler spectral and mitral and tricuspid tissue parameters as well as the global longitudinal strain of both ventricles. We studied right ventricle global longitudinal strain (RVGLS), septal wall longitudinal strain (RVSWLS), right ventricle lateral wall longitudinal strain (RVLWLS).

Results:
we studied a group of 61 patients who presented with essential hypertension, recently diagnosed, with an average age of 68.1 +- 6.3 years and who were analyzed according to grade, gender, risk factors. The (RVGLS) was analyzed separately and comparatively for the lateral and septal wall and the values were RVGLS =19%+- 3.2%. RVSWLS=-13.1% +-2.9% and RVFWLS=-22.6%+- 3.4%. The filling ratio of the right ventricle E/e’ was 14.

Conclusions:
the diastolic function of the right ventricle is affected in recently diagnosed hypertensive patients in relation to the degree of hypertension, myocardial mass and the filling ratio of the left ventricle. Slightly increased values of RVLWGLS could be interpreted as a consequence of sympathetic activation
EFFECT OF HIGH DOSE APROCITENTAN IN PATIENTS WITH RESISTANT HYPERTENSION NOT CONTROLLED BY LOW DOSE
Authors: Narkiewicz Krzysztof , Danaietash Parisa , Gimona Alberto , Kania Grzegorz , Kantola Ilkka , Martinez-garcia Fernando , Sassi-sayadi Mouna , Schlaich Markus P , Toursarkissian Nicole , Wang Ji -GUANG , Weber Michael A 
Published: May 2024

Objective:
The phase 3 PRECISION study in patients with resistant hypertension tested 12.5 mg and 25 mg aprocitentan during the 4-week DB placebo-controlled part, in addition to a fixed-dose combination of amlodipine, valsartan, hydrochlorothiazide. No differences in primary endpoint (SiSBP) were observed between the two doses. This post-hoc exploratory analysis evaluates the observed long-term benefit of increasing to a higher dose (25 mg) in patients not achieving a blood pressure control after 4 weeks on the lower dose (12.5 mg).

Design and method:
In PRECISION, after completion of the 4-week DB part 1, all randomized patients received 25 mg aprocitentan during the 32-week SB part 2. This subgroup analysis includes 93 subjects who were still uncontrolled at week 4 (SiSBP > 140 mm/Hg) in the 12.5 mg aprocitentan group (n=223). The % of patients achieving control (<140 or < 130 for SiSBP and < 90 or < 85 mm/Hg for SiDBP) or showing a response of >/= -10 or >/= -15 mmHg in SiSBP or >/= -5 or >/= -10 mm/Hg in SiDBP vs week 4 at week 6, 12 and 36 (i.e., after 2 to 32 weeks of treatment with 25 mg) were calculated.

Results:
Among the patients in the aprocitentan 12.5 mg group with uncontrolled SiSBP at 4 weeks, after 2 weeks of treatment with 25 mg (at study Week 6), 39.8% (37/93) of subjects achieved SiSBP < 140 mmHg. This increased to 49.3% (37/73) after 32 weeks of aprocitentan 25 mg treatment, at study week 36. The control rate set at the 130 mm Hg threshold and the response rates also increased over time. Also, for SiDBP the increase in the dose of aprocitentan resulted in a high proportion of patients being controlled (45% to 68% depending on the threshold) and responders (45 to 68%) after 32 weeks of treatment.

Conclusions:
These additional exploratory analyses show that switching from 12.5 mg to 25 mg aprocitentan can achieve further BP control or response not obtained with the lower dose.
EVALUATION OF THYROID FUNCTION AND THYROID DISEASES IN PATIENTS WITH PRIMARY ALDOSTERONISM
Authors: Maiturouzi Mayire , Zhu Qing , Zhang Delian , Li Nanfang , Wu Ting , Liu Shasha , Luo Qin , Wang Menghui , Heizhati Mulalibieke , Cai Xintian , Cai Li , Dang Yujie , Aimudula Adilakezi 
Published: May 2024

Objective:
To explored the thyroid function and prevalence of thyroid diseases in primary aldosteronism (PA) and PA subtypes.

Design and method:
Patients with PA and Essential hypertension (EH) in our hypertension center between August 2011 to June 2022 were enrolled in this observational study. All PA patients underwent adrenal venous sampling (AVS), thus receiving the most accurate subtype diagnosis available. The differences of thyroid function and the prevalence of thyroid diseases between PA and EH patients were analyzed.

Results:
7161 participants were included in the study with a mean age of 48.20±8.83 years and a mean BMI of 26.52±3.45 kg/m2. Two groups: PA patients showed lower FT4, FT3, TT4, TT3, positive TPOAb and higher prevalence of thyroid nodules (22.5%) than EH patients. PA was significantly associated with thyroid nodules (OR: 1.245, 95%CI: 1.052-1.473, P= 0.011). Three groups: statistical differences in FT4, FT3, TT4, TT3, and positive TPOAb levels were found in APA, IHA and EH. Thyroid nodules are most prevalent in APA (26.00%), followed by IHA (20.80%) and EH (17.80%). APA showed a significant association with thyroid nodules (OR: 1.345, 95%CI: 1.015-1.781, P=0.039). Additionally, it was found that FT4, FT3, TT4, and TT3 were negatively correlated with the PAC levels in patients. The stratification analysis showed that the prevalence of thyroid nodules was higher in subjects with PAC levels great than or equal to 12ng/dL.

Conclusions:
Compared to EH groups, PA patients had lower thyroid function and higher prevalence of thyroid nodules.
TO EXPLORED THE THYROID FUNCTION AND PREVALENCE OF THYROID DISEASES IN PRIMARY ALDOSTERONISM (PA) AND PA SUBTYPES
Authors: Maiturouzi Mayire , Zhu Qing , Zhang Delian , Li Nanfang , Wu Ting , Liu Shasha , Luo Qin , Heizhati Mulalibieke , Wang Menghui , Cai Li , Cai Xintian , Dang Yujie , Aimudula Adilakezi 
Published: May 2024

Objective:
To explored the thyroid function and prevalence of thyroid diseases in primary aldosteronism (PA) and PA subtypes.

Design and method:
Patients with PA and Essential hypertension (EH) in our hypertension center between August 2011 to June 2022 were enrolled in this observational study. All PA patients underwent adrenal venous sampling (AVS), thus receiving the most accurate subtype diagnosis available. The differences of thyroid function and the prevalence of thyroid diseases between PA and EH patients were analyzed.

Results:
7161 participants were included in the study with a mean age of 48.20±8.83 years and a mean BMI of 26.52±3.45 kg/m2. Two groups: PA patients showed lower FT4, FT3, TT4, TT3, positive TPOAb and higher prevalence of thyroid nodules (22.5%) than EH patients. PA was significantly associated with thyroid nodules (OR: 1.245, 95%CI: 1.052-1.473, P= 0.011). Three groups: statistical differences in FT4, FT3, TT4, TT3, and positive TPOAb levels were found in APA, IHA and EH. Thyroid nodules are most prevalent in APA (26.00%), followed by IHA (20.80%) and EH (17.80%). APA showed a significant association with thyroid nodules (OR: 1.345, 95%CI: 1.015-1.781, P=0.039). Additionally, it was found that FT4, FT3, TT4, and TT3 were negatively correlated with the PAC levels in patients. The stratification analysis showed that the prevalence of thyroid nodules was higher in subjects with PAC leve greater than or equal to 12ng/dL.

Conclusions:
Compared to EH groups, PA patients had lower thyroid function and higher prevalence of thyroid nodules.
IMPROVEMENT OF RENAL HAEMODYNAMICS AND ECHOCARDIOGRAPHIC PARAMETERS IN PHARMACOLOGICAL CONTROLLED HYPERTENSIVES
Authors: De Rosa Maria Leonarda , Atripaldi Luigi Giuseppe , Iovine Sabrina , Ferrara Nicola 
Published: May 2024

Objective:
A study was carried out to evaluate the influence of blood pressure lowering treatment with combined doses of olmesartan plus amplodipina compared with those of either drug at a single dose level.

Design and method:
By double-blind, three-way crossover study (balanced Latin square design) in 102 subjects (mean age 51.9 +/- 7.42 years) with essential hypertension we used Olmesartan 40 mg plus Amplodine 5 mg compared with those of either drug at a single and higher dose level (40 or 10 mg daily, respectively). Left ventricular mass and function were evaluated by M-B mode echocardiography, renal function by glomerular filtration rate (GFR) and by serum and 24-h urinary Na+ and K+ during wash-out period and after 24 weeks of treatment.

Results:
The supine blood pressure for subjects given placebo was 171/103 mmHg. After 24 weeks of treatment, systolic and diastolic supine blood pressure were significantly lower with 40 mg iolmesartan plus 5 mg amplodipine (134/84 mmHg) than with 10 mg amplodipine (137/84 mmHg) or with 40 mg olmesartan (144/85 mmHg). Left ventricular posterior wall and septal thickness were significantly and similarly reduced in all groups. Left ventricular systolic and diastolic end diameters were not significantly changed. Left ventricular mass (LVM) was significantly reduced in Olmesartan plus Amplodipine group and Olmesartan group. GFR was not significantly altered. The 24-h urinary Na+ significantly increased with olmesartan, more so than amplodipine. The combination was tolerated better than either monotherapy. We observed no clinically significant changes in laboratory variables including blood lipoproteins.

Conclusions:
The combination of olmesartan plus amplodipina reduced blood pressure more effectively and was better tolerated than other drug alone. All three groups showed similar changes in echocardiographic indices and no change in renal function.
GENDER DISPARITIES IN HYPERTENSIVE PATIENTS ACROSS THE LIFETIME: AN AGE-STRATIFIED ANALYSIS
Authors: Marozzi Marialuisa Sveva , Corvasce Francesco , Persia Simona , Desantis Vanessa , Amodio Gianfranco , Santoro Giuseppe , Falcone Giuseppe , Vacca Angelo , Cicco Sebastiano 
Published: May 2024

Objective:
This study aims to explore the influence of gender on vascular and renal damage across distinct age brackets. In particular, investigates the intricate interplay between gender, aging and the onset of vascular and renal injuries. Additionally, the study incorporates an examination of the Triglyceride-Glucose (TYG) index, a surrogate indicator of insulin resistance, to discern its role in clarifying gender-specific variations in health outcomes across different life stages. This analysis aims to enhance our comprehension of age-specific vulnerabilities and contribute valuable insights to the field of gender-related health research.

Design and method:
We selected 210 Caucasian patients, all affected by hypertension, and we divided them previously in two groups, male and female, and in each group we splitted 3 clusters based on their age (under 50, 50 to 70 and over 70 years old). All patients underwent a comprehensive physical examination, with systolic blood pressure (SBP), diastolic blood pressure (DBP) and heart rate (HR). Blood samples obtained from all patients were analyzed for the complete blood count, low/high density lipoproteins and triglycerides, glycaemia and renal function, including albuminuria and proteinuria. Moreover, all patients went through ankle-brachial index (ABI) and pulse wave velocity. Lastly we calculated the TYG index of all patients.

Results:
Regardless of the well-known correlation between TYG index and hypertension, we found that there was no gender difference between the TyG index and gender or aging. Moreover, no differences were underlined among vascular and renal injuries, neither changes in aortic stiffness were associated to gender but to age-related effects

Conclusions:
Despite what expected, the menopausal transition was not associated with a higher renal or vascular damage, nor to a higher risk of insulin resistance. Large-scale prospective cohort studies are needed to validate these findings, also detecting the influence of gender and aging on heart damage.
CORRELATION ANALYSIS BETWEEN VASCULAR OVERLOAD INDEX AND LEFT VENTRICULAR HYPERTROPHY IN HYPERTENSION
Authors: Zhang Wenchen , Yue Jianwei , Yue Jianwei 
Published: May 2024

Objective:
The vascular overload index (VOI) is commonly used to assess the’overload’phenomenon induced by hypertension,and vascular overload is one of the pathogenic mechanisms for left ventricular hypertrophy(LVH)associated with hypertension. The left ventricular mass index (LVMI) is the most frequently used diagnostic indicator for LVH. Research has found that VOI derived from office blood pressure readings is correlated with LVH,but it doesn’t evaluate the relationship between vascular load during different periods of the day and LVH. This study aims to investigate the correlation between VOI obtained from 24-hour ambulatory blood pressure and LVH.

Design and method:
A total of 591 hypertensive patients hospitalized from July 2020 to July 2022 were included. Echocardiography was performed in each patient,and the LVMI was calculated; The 24-hour VOI(VOI24h=1.33×SBP24h-0.33×DBP24h-133.3mmHg),daytime VOI(VOId),and nighttime VOI(VOIn)were calculated based on the 24-hour ambulatory blood pressure results. A multivariate logistic regression was utilized to explore the correlation between VOI at different times and LVH,adjusting for covariates such as gender,age,BMI,triglycerides,cholesterol,HDLand LDL.

Results:
The age of the 591 hypertensive patients was 63.8±13.3years and BMI was 25.7±3.6Kg/m2.Univariate linear regression analysis showed that VOI24h,VOId,and VOIn were positively correlated with LVMI(P<0.001). After adjusting,all of VOI remained correlated with LVMI. Compared with the lowest tertile of VOI24h, the highest tertile had β (95%CI) of 9.25(6.09∼12.4). For VOId,the highest tertile compared to the lowest had β (95%CI) of 8.70(5.55∼11.86),and for VOIn,it was 9.48(6.32∼12.64).Univariate logistic regression analysis indicated that all of VOI were significantly associated with LVH(P<0.001),and after adjusting for confounders,all of VOI still correlated with LVH,with OR(95%CI)respectively being 1.04(1.02∼1.07),1.04(1.02∼1.07),and 1.03(1.01∼1.05). Subgroup analysis revealed that regardless of the comorbidity of the hypertensive patients,all of VOI were all related to LVH.However, when analyzed by season,VOI24h and VOId were significantly associated with LVH in summer and winter, but not in spring and autumn; VOIn was only associated with LVH in winter.

Conclusions:
In the hypertensive patients,VOI derived from 24-hour ambulatory blood pressure is significantly correlated with LVH. Compared to spring and autumn,vascular load during summer and winter is significantly associated with LVH. Therefore,not only should steady blood pressure control over 24 hours be emphasized,but also pay attention to the impact of vascular load on LVH during summer and winter.
LIPIDS INCREASE IN HYPERTENSIVES DURING THE FIRST YEAR STEROID TREATMENT FOR GRANULOMATOSIS WITH POLYANGIITIS (GPA)
Authors: Marozzi Marialuisa Sveva , Corvasce Francesco , Desantis Vanessa , Noviello Silvia , Cirulli Anna , Solimando Antonio Giovanni , Ria Roberto , Vacca Angelo , Cicco Sebastiano 
Published: May 2024

Objective:
Granulomatosis with polyangiitis (GPA) is an ANCA-associated small-vessel vasculitis. Vessel wall inflammation induces multiple vascular damages leading to accelerated atherosclerosis. Metabolic profile and cardiovascular risk are marginally known in the GPA patients. Our purpose is to evaluate lipid profile and ASCVD-risk in GPA patients.

Design and method:
We selected 36 patients who received GPA diagnosis (T0) and evaluated them after 1 (T1) and 2 (T2) years follow-up. All patients were treated with high-dose glucocorticoid, one-year tapered, associated with immunosuppressants. Pathological history and a complete list of drugs at different time points were recorded.

Results:
The study reveals noteworthy alterations in lipid profiles, with a substantial increase observed in total cholesterol during both T1 and T2 in comparison to T0. A similar trend was noted in LDLand triglycerides. Conversely, no discernible differences were identified in HDL levels. Additionally, a considerable decrease in high-sensitivity C-reactive protein was observed at T1 and T2 in relation to T0, with no significant variance between T2 and T1. Furthermore, a notable reduction in erythrocyte sedimentation rate was noted at T2 as opposed to both T1 and T0, as well as at T1 compared to T0. Moreover, an interesting observation pertains to hypertensive patients who exhibited a marked escalation in lipid levels, juxtaposed with a gradual reduction in inflammation when compared to normotensive individuals. In particular, notable distinctions emerge between the two groups at both T1 and T2 concerning total cholesterol and LDL (p=0.027), despite comparable baseline values at T0. Then, while triglyceride levels start at similar values at T0, a substantial increase is observed at T1 in hypertensive patients and, conversely, at T2, normotensive individuals experience a significant rise in triglyceride levels, accompanied by a noteworthy reduction in hypertensive subjects.

Conclusions:
The findings indicate that lipid profile alterations, likely influenced by glucocorticoid treatment, may not be directly linked to inflammation. Furthermore, there is a higher relation between hypertension and these alterations. Actual data doesn’t reveal increased mortality in hypertensive GPA patients but further research is required to pinpoint specific patterns characterizing cardiovascular risk and progression in this context.
STATUS AND SURVIVAL RISK OF PATIENTS WITH CHRONIC KIDNEY DISEASE AND HYPERTENSION
Authors: Tian Yixin , Wang Zengwu , Cao Xue , Hu Zhen 
Published: May 2024

Objective:
To provide nationwide data on status of control and survival risk of patients with hypertension and chronic kidney disease in China.

Design and method:
A total of 39,094 participants aged 35 years and above, without prior cardiovascular disease (CVD), were enrolled from a sub-study of the China Hypertension Survey. CKD defined as presence of impaired kidney function (eGFR of <60 mL/min/1.73m2). Hypertension defined as 140/90 mmHg or higher. CVD events and all-cause mortality, with follow-up from 2018 to 2019. Multivariable Cox proportional hazards models were employed to estimate hazard ratios (HRs) of patients with CKD in Chinese adults with hypertension.

Results:
The mean age was 56.18 years, and the proportion of women was 54.4%. There were 16 276 adults with hypertension. The estimated proportion of CKD in patients with hypertension were 15.79% in China. The proportions of CKD were 13.22%, 17.26%, 21.64% at stage 1, 2, and 3 hypertension, respectively. Among the adults with hypertension, 21.07%, 63.14%, 13.07%, 2.32%, and 0.4% were at stage 1, 2, 3a, 3b, and 4 to 5 CKD, respectively. In patients with hypertension and CKD, the proportions of combined use of 2 or more antihypertensive drugs were 3.87%, 7.37%, 9.41%, 14.79%, and 10.80%, and the control rate of hypertension were 15.13%, 19.74%, 22.94%, 24.60%, and 21.54% at stage 1, 2, 3a, 3b, and 4 to 5 CKD, respectively. Among the hypertensive patients, after adjusting for age, sex, educational levels, alcohol drinking, smoking, and BMI, people with CKD had 58.8% higher risk of CVD (HR=1.588, 95%CI 1.341–1.881) and 34.3% higher risk in all-cause mortality (HR=1.343, 95%CI 1.138–1.584), compared with people without CKD. Significant higher risk of CVD and mortality at 3a, 3b, 4 to 5 CKD compared with stage 1 CKD.

Conclusions:
Among Chinese adults with hypertension, the proportion of CKD increased with higher blood pressure. Patients with hypertension and CKD had limited control rates of hypertension and high risks of CVD and all-cause mortality, which need more attention.